This G-BA category includes all medicinal products for the prevention of stroke, heart attack, heart failure or venous thromboembolism such as pulmonary embolism or deep vein thrombosis, as well as antihypertensives.

To date, the G-BA has assessed XX different medicinal products in XX procedures, which in turn were divided into xx subpopulations. When these subpopulations are weighted according to their share of the total number of patients in the resolution, there is a major additional benefit for xx% and a considerable additional benefit for XX% of the subpopulations. The G-BA has confirmed a minor additional benefit for XX% and a non-quantifiable additional benefit for another XX% in relation to the comparative treatment. The G-BA did recognise no additional benefit for XX% of the subpopulations, corresponding to xx% of the potential total number of all patients using these medicinal products.